Illinois 2023-2024 Regular Session

Illinois House Bill HB4472 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4472 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED: New Act30 ILCS 105/5.1015 new Creates the Health Care Availability and Access Board Act. Establishes the Health Care Availability and Access Board to protect State residents, State and local governments, commercial health plans, health care providers, pharmacies licensed in the State, and other stakeholders within the health care system from the high costs of prescription drug products. Contains provisions concerning Board membership and terms; staff for the Board; Board meetings; circumstances under which Board members must recuse themselves; and other matters. Provides that the Board shall perform the following actions in open session: (i) deliberations on whether to subject a prescription drug product to a cost review; and (ii) any vote on whether to impose an upper payment limit on purchases, payments, and payor reimbursements of prescription drug products in the State. Permits the Board to adopt rules to implement the Act and to enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the Board. Creates the Health Care Availability and Access Stakeholder Council to provide stakeholder input to assist the Board in making decisions as required by the Act. Contains provisions concerning Council membership, member terms, and other matters. Provides that the Board shall adopt the federal Medicare Maximum Fair Price as the upper payment limit for a prescription drug product intended for use by individuals in the State. Requires the Attorney General to enforce the Act. Effective 180 days after becoming law. LRB103 36317 CES 67585 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4472 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED: New Act30 ILCS 105/5.1015 new New Act 30 ILCS 105/5.1015 new Creates the Health Care Availability and Access Board Act. Establishes the Health Care Availability and Access Board to protect State residents, State and local governments, commercial health plans, health care providers, pharmacies licensed in the State, and other stakeholders within the health care system from the high costs of prescription drug products. Contains provisions concerning Board membership and terms; staff for the Board; Board meetings; circumstances under which Board members must recuse themselves; and other matters. Provides that the Board shall perform the following actions in open session: (i) deliberations on whether to subject a prescription drug product to a cost review; and (ii) any vote on whether to impose an upper payment limit on purchases, payments, and payor reimbursements of prescription drug products in the State. Permits the Board to adopt rules to implement the Act and to enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the Board. Creates the Health Care Availability and Access Stakeholder Council to provide stakeholder input to assist the Board in making decisions as required by the Act. Contains provisions concerning Council membership, member terms, and other matters. Provides that the Board shall adopt the federal Medicare Maximum Fair Price as the upper payment limit for a prescription drug product intended for use by individuals in the State. Requires the Attorney General to enforce the Act. Effective 180 days after becoming law. LRB103 36317 CES 67585 b LRB103 36317 CES 67585 b A BILL FOR
2	2	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4472 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED:
3	3	New Act30 ILCS 105/5.1015 new New Act 30 ILCS 105/5.1015 new
4	4	New Act
5	5	30 ILCS 105/5.1015 new
6	6	Creates the Health Care Availability and Access Board Act. Establishes the Health Care Availability and Access Board to protect State residents, State and local governments, commercial health plans, health care providers, pharmacies licensed in the State, and other stakeholders within the health care system from the high costs of prescription drug products. Contains provisions concerning Board membership and terms; staff for the Board; Board meetings; circumstances under which Board members must recuse themselves; and other matters. Provides that the Board shall perform the following actions in open session: (i) deliberations on whether to subject a prescription drug product to a cost review; and (ii) any vote on whether to impose an upper payment limit on purchases, payments, and payor reimbursements of prescription drug products in the State. Permits the Board to adopt rules to implement the Act and to enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the Board. Creates the Health Care Availability and Access Stakeholder Council to provide stakeholder input to assist the Board in making decisions as required by the Act. Contains provisions concerning Council membership, member terms, and other matters. Provides that the Board shall adopt the federal Medicare Maximum Fair Price as the upper payment limit for a prescription drug product intended for use by individuals in the State. Requires the Attorney General to enforce the Act. Effective 180 days after becoming law.
7	7	LRB103 36317 CES 67585 b LRB103 36317 CES 67585 b
8	8	LRB103 36317 CES 67585 b
9	9	A BILL FOR
10	10	HB4472LRB103 36317 CES 67585 b HB4472 LRB103 36317 CES 67585 b
11	11	HB4472 LRB103 36317 CES 67585 b
12	12	1 AN ACT concerning health.
13	13	2 Be it enacted by the People of the State of Illinois,
14	14	3 represented in the General Assembly:
15	15	4 Section 1. Short title. This Act may be cited as the Health
16	16	5 Care Availability and Access Board Act.
17	17	6 Section 5. Definitions. In this Act:
18	18	7 "Biologic" means a drug that is produced or distributed in
19	19	8 accordance with a biologics license application approved under
20	20	9 42 U.S.C. 447.502.
21	21	10 "Biosimilar" means a drug that is produced or distributed
22	22	11 in accordance with a biologics license application approved
23	23	12 under 42 U.S.C. 262(k)(3).
24	24	13 "Board" means the Health Care Availability and Access
25	25	14 Board.
26	26	15 "Brand name drug" means a drug that is produced or
27	27	16 distributed in accordance with an original new drug
28	28	17 application approved under 21 U.S.C. 355(c). "Brand name drug"
29	29	18 does not include an authorized generic drug as defined by 42
30	30	19 CFR 447.502.
31	31	20 "Council" means the Health Care Availability and Access
32	32	21 Stakeholder Council.
33	33	22 "Generic drug" means:
34	34	23 (1) a retail drug that is marketed or distributed in
35	35
36	36
37	37
38	38	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4472 Introduced , by Rep. Nabeela Syed SYNOPSIS AS INTRODUCED:
39	39	New Act30 ILCS 105/5.1015 new New Act 30 ILCS 105/5.1015 new
40	40	New Act
41	41	30 ILCS 105/5.1015 new
42	42	Creates the Health Care Availability and Access Board Act. Establishes the Health Care Availability and Access Board to protect State residents, State and local governments, commercial health plans, health care providers, pharmacies licensed in the State, and other stakeholders within the health care system from the high costs of prescription drug products. Contains provisions concerning Board membership and terms; staff for the Board; Board meetings; circumstances under which Board members must recuse themselves; and other matters. Provides that the Board shall perform the following actions in open session: (i) deliberations on whether to subject a prescription drug product to a cost review; and (ii) any vote on whether to impose an upper payment limit on purchases, payments, and payor reimbursements of prescription drug products in the State. Permits the Board to adopt rules to implement the Act and to enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the Board. Creates the Health Care Availability and Access Stakeholder Council to provide stakeholder input to assist the Board in making decisions as required by the Act. Contains provisions concerning Council membership, member terms, and other matters. Provides that the Board shall adopt the federal Medicare Maximum Fair Price as the upper payment limit for a prescription drug product intended for use by individuals in the State. Requires the Attorney General to enforce the Act. Effective 180 days after becoming law.
43	43	LRB103 36317 CES 67585 b LRB103 36317 CES 67585 b
44	44	LRB103 36317 CES 67585 b
45	45	A BILL FOR
46	46
47	47
48	48
49	49
50	50
51	51	New Act
52	52	30 ILCS 105/5.1015 new
53	53
54	54
55	55
56	56	LRB103 36317 CES 67585 b
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66	HB4472 LRB103 36317 CES 67585 b
67	67
68	68
69	69	HB4472- 2 -LRB103 36317 CES 67585 b HB4472 - 2 - LRB103 36317 CES 67585 b
70	70	HB4472 - 2 - LRB103 36317 CES 67585 b
71	71	1 accordance with an abbreviated new drug application,
72	72	2 approved under 21 U.S.C. 355(j);
73	73	3 (2) an authorized generic drug as defined by 42 CFR
74	74	4 447.502; or
75	75	5 (3) a drug that entered the market before 1962 that
76	76	6 was not originally marketed under a new drug application.
77	77	7 "Manufacturer" means an entity that:
78	78	8 (1) owns the patent to a prescription drug product; or
79	79	9 (2) enters into a lease with another manufacturer to
80	80	10 market and distribute a prescription drug product under
81	81	11 the entity's own name;
82	82	12 (3) is the labeled entity of the generic product at
83	83	13 the point of manufacture; and
84	84	14 (4) sets or changes the wholesale acquisition cost of
85	85	15 the prescription drug product it manufactures or markets.
86	86	16 "Prescription drug product" means a brand name drug, a
87	87	17 generic drug, a biologic, or a biosimilar.
88	88	18 Section 10. Health Care Availability and Access Board.
89	89	19 (a) There is established a Health Care Availability and
90	90	20 Access Board. The purpose of the Board is to protect State
91	91	21 residents, State and local governments, commercial health
92	92	22 plans, health care providers, pharmacies licensed in the
93	93	23 State, and other stakeholders within the health care system
94	94	24 from the high costs of prescription drug products. The Board
95	95	25 is a public body and is an instrumentality of the State. The
96	96
97	97
98	98
99	99
100	100
101	101	HB4472 - 2 - LRB103 36317 CES 67585 b
102	102
103	103
104	104	HB4472- 3 -LRB103 36317 CES 67585 b HB4472 - 3 - LRB103 36317 CES 67585 b
105	105	HB4472 - 3 - LRB103 36317 CES 67585 b
106	106	1 Board is an independent unit of State government. The exercise
107	107	2 by the Board of its authority under this Act is an essential
108	108	3 function.
109	109	4 (b)(1) The 5 members of the Board and 3 alternate members
110	110	5 shall be appointed by the Governor with the advice and consent
111	111	6 of the Senate.
112	112	7 (2) The Board membership must include individuals with
113	113	8 demonstrated expertise in health care economics,
114	114	9 pharmaceutical market, and clinical medicine. A member or an
115	115	10 alternate member may not be an employee of, a Board member of,
116	116	11 or a consultant to a manufacturer or trade association for
117	117	12 manufacturers.
118	118	13 (3) Any conflict of interest, including whether the
119	119	14 individual has an association, including a financial or
120	120	15 personal association, that has the potential to bias or has
121	121	16 the appearance of biasing an individual's decision in matters
122	122	17 related to the Board or the conduct of the Board's activities,
123	123	18 shall be considered and disclosed when appointing members and
124	124	19 alternate members to the Board.
125	125	20 (c) The term of a member or an alternate member is 5 years,
126	126	21 except that the terms of the initial members and alternate
127	127	22 members shall be staggered as required by the terms provided
128	128	23 for members in Section 55. Initial Board members shall be
129	129	24 appointed within 4 months after the effective date of this
130	130	25 Act. The Board may begin its work if there is a delay in
131	131	26 appointments to the Health Care Availability and Access
132	132
133	133
134	134
135	135
136	136
137	137	HB4472 - 3 - LRB103 36317 CES 67585 b
138	138
139	139
140	140	HB4472- 4 -LRB103 36317 CES 67585 b HB4472 - 4 - LRB103 36317 CES 67585 b
141	141	HB4472 - 4 - LRB103 36317 CES 67585 b
142	142	1 Stakeholder Council created under Section 20.
143	143	2 (d) The Chair shall hire an executive director, general
144	144	3 counsel, and staff for the Board. Staff of the Board shall
145	145	4 receive a salary as provided in the budget of the Board. A
146	146	5 member of the Board: (i) may receive compensation as a member
147	147	6 of the Board; and (ii) is entitled to reimbursement for
148	148	7 expenses.
149	149	8 (e) A majority of the members of the Board shall
150	150	9 constitute a quorum for the purposes of conducting the
151	151	10 business of the Board.
152	152	11 (f) Subject to the requirements of this subsection, the
153	153	12 Board shall meet in open session at least 4 times per year to
154	154	13 review prescription drug product information. Information
155	155	14 concerning the location, date, and time of the meeting must be
156	156	15 made publicly available in accordance with the Open Meetings
157	157	16 Act. The Chair may cancel or postpone a meeting if there are no
158	158	17 prescription drug products to review.
159	159	18 The Board shall perform the following actions in open
160	160	19 session: (i) deliberations on whether to subject a
161	161	20 prescription drug product to a cost review under subsection
162	162	21 (f) of Section 25; and (ii) any vote on whether to impose an
163	163	22 upper payment limit on purchases, payments, and payor
164	164	23 reimbursements of prescription drug products in the State. The
165	165	24 Board may otherwise meet in closed session to discuss
166	166	25 proprietary data and information.
167	167	26 The Board shall provide public notice of each Board
168	168
169	169
170	170
171	171
172	172
173	173	HB4472 - 4 - LRB103 36317 CES 67585 b
174	174
175	175
176	176	HB4472- 5 -LRB103 36317 CES 67585 b HB4472 - 5 - LRB103 36317 CES 67585 b
177	177	HB4472 - 5 - LRB103 36317 CES 67585 b
178	178	1 meeting at least 3 weeks in advance of the meeting. Materials
179	179	2 for each Board meeting shall be made available to the public at
180	180	3 least 3 weeks in advance of the meeting. The Board shall
181	181	4 provide an opportunity for public comment at each open meeting
182	182	5 of the Board. The Board shall provide the public with the
183	183	6 opportunity to provide written comments on pending decisions
184	184	7 of the Board. The Board may allow expert testimony at Board
185	185	8 meetings, including when the Board meets in closed session.
186	186	9 (g)(1) Members of the Board shall recuse themselves from
187	187	10 decisions related to a prescription drug product if the
188	188	11 member, or an immediate family member of the member, has
189	189	12 received or could receive any of the following:
190	190	13 (A) a direct financial benefit of any amount deriving
191	191	14 from the result or finding of a study or determination by
192	192	15 or for the Board; or
193	193	16 (B) a financial benefit from any person who owns,
194	194	17 manufactures, or provides prescription drug products,
195	195	18 services, or items to be studied by the Board that in the
196	196	19 aggregate exceeds $5,000 per year.
197	197	20 A disclosure of interests under this paragraph shall
198	198	21 include the type, nature, and magnitude of the interests of
199	199	22 the member or his or her immediate family member involved.
200	200	23 For the purposes of this paragraph, "financial benefit"
201	201	24 includes honoraria, fees, stock, the value of the member's or
202	202	25 immediate family member's stock holdings, and any direct
203	203	26 financial benefit deriving from the finding of a review
204	204
205	205
206	206
207	207
208	208
209	209	HB4472 - 5 - LRB103 36317 CES 67585 b
210	210
211	211
212	212	HB4472- 6 -LRB103 36317 CES 67585 b HB4472 - 6 - LRB103 36317 CES 67585 b
213	213	HB4472 - 6 - LRB103 36317 CES 67585 b
214	214	1 conducted under this Act.
215	215	2 (2) A conflict of interest shall be disclosed in advance
216	216	3 of the first open meeting after the conflict is identified or
217	217	4 within 5 days after the conflict is identified. A conflict of
218	218	5 interest shall be disclosed by:
219	219	6 (A) the Board when hiring Board staff;
220	220	7 (B) the appointing authority when appointing members
221	221	8 and alternate members to the Board and members to the
222	222	9 Council; and
223	223	10 (C) the Board when a member of the Board is recused in
224	224	11 any final decision resulting from a review of a
225	225	12 prescription drug product.
226	226	13 (3) A conflict of interest disclosed under this Section
227	227	14 shall be posted on the website of the Board unless the Chair of
228	228	15 the Board recuses the member from any final decision resulting
229	229	16 from a review of a prescription drug product.
230	230	17 (4) Members and alternate members of the Board, Board
231	231	18 staff, and third-party contractors may not accept any gift or
232	232	19 donation of services or property that indicates a potential
233	233	20 conflict of interest or has the appearance of biasing the work
234	234	21 of the Board.
235	235	22 Section 15. Powers and duties of the Board. In addition to
236	236	23 the powers set forth elsewhere in this Act, the Board may:
237	237	24 (1) adopt rules for the implementation of this Act;
238	238	25 and
239	239
240	240
241	241
242	242
243	243
244	244	HB4472 - 6 - LRB103 36317 CES 67585 b
245	245
246	246
247	247	HB4472- 7 -LRB103 36317 CES 67585 b HB4472 - 7 - LRB103 36317 CES 67585 b
248	248	HB4472 - 7 - LRB103 36317 CES 67585 b
249	249	1 (2) enter into a contract with a qualified,
250	250	2 independent third party for any service necessary to carry
251	251	3 out the powers and duties of the Board.
252	252	4 Unless permission is granted by the Board, a third party
253	253	5 hired by the Board may not release, publish, or otherwise use
254	254	6 any information to which the third party has access under its
255	255	7 contract.
256	256	8 Section 20. Health Care Availability and Access
257	257	9 Stakeholder Council.
258	258	10 (a) The Health Care Availability and Access Stakeholder
259	259	11 Council is created. The purpose of the Council is to provide
260	260	12 stakeholder input to assist the Board in making decisions as
261	261	13 required under this Act. The Council consists of 15 members
262	262	14 appointed within 4 months after the effective date of this Act
263	263	15 as follows:
264	264	16 (1) 3 members appointed by the Speaker of the House of
265	265	17 Representatives;
266	266	18 (2) 2 members appointed by the Minority Leader of the
267	267	19 House of Representatives;
268	268	20 (3) 3 members appointed by the President of the
269	269	21 Senate;
270	270	22 (4) 2 members appointed by the Minority Leader of the
271	271	23 Senate; and
272	272	24 (5) 5 members appointed by the Governor.
273	273	25 (b) The members of the Council shall have knowledge in one
274	274
275	275
276	276
277	277
278	278
279	279	HB4472 - 7 - LRB103 36317 CES 67585 b
280	280
281	281
282	282	HB4472- 8 -LRB103 36317 CES 67585 b HB4472 - 8 - LRB103 36317 CES 67585 b
283	283	HB4472 - 8 - LRB103 36317 CES 67585 b
284	284	1 or more of the following:
285	285	2 (1) the pharmaceutical business model;
286	286	3 (2) supply chain business models;
287	287	4 (3) the practice of medicine or clinical training;
288	288	5 (4) consumer or patient perspectives;
289	289	6 (5) clinical and health services research; or
290	290	7 (6) the State's health care marketplace.
291	291	8 (c) From among the membership of the Council, the Board
292	292	9 Chair shall appoint one member to be Council Chair.
293	293	10 (d) The term of a member is 3 years, except that the
294	294	11 initial members of the Council shall serve staggered terms as
295	295	12 required by the terms provided for members in Section 55.
296	296	13 (e) A member of the Council may not receive compensation
297	297	14 as a member of the Council, but is entitled to reimbursement
298	298	15 for travel expenses.
299	299	16 Section 25. Drug cost affordability review.
300	300	17 (a) The Board shall limit its review of prescription drug
301	301	18 products to those that are:
302	302	19 (1) brand name drugs or biologics that, as adjusted
303	303	20 annually for inflation in accordance with the Consumer
304	304	21 Price Index, have:
305	305	22 (A) a wholesale acquisition cost of $60,000 or
306	306	23 more per year or course of treatment if less than a
307	307	24 year; or
308	308	25 (B) a wholesale acquisition cost increase of
309	309
310	310
311	311
312	312
313	313
314	314	HB4472 - 8 - LRB103 36317 CES 67585 b
315	315
316	316
317	317	HB4472- 9 -LRB103 36317 CES 67585 b HB4472 - 9 - LRB103 36317 CES 67585 b
318	318	HB4472 - 9 - LRB103 36317 CES 67585 b
319	319	1 $3,000 or more in any 12-month period;
320	320	2 (2) biosimilar drugs that have a wholesale acquisition
321	321	3 cost that is not at least 20% lower than the referenced
322	322	4 brand biologic at the time the biosimilars are launched,
323	323	5 and that have been suggested for review by the members of
324	324	6 public, medical professionals, and other stakeholders;
325	325	7 (3) generic drugs that, as adjusted annually for
326	326	8 inflation in accordance with the Consumer Price Index,
327	327	9 have a wholesale acquisition cost of at least $100 for a
328	328	10 30-day supply or course of treatment less than 30 days and
329	329	11 which increased by 200% or more during the immediately
330	330	12 preceding 12-month period, as determined by the difference
331	331	13 between the resulting wholesale acquisition cost and the
332	332	14 average of the wholesale acquisition cost reported over
333	333	15 the immediately preceding 12 months; and
334	334	16 (4) other prescription drug products that may create
335	335	17 affordability challenges for the State health care system
336	336	18 or patients, including, but not limited to, drugs to
337	337	19 address public health emergencies.
338	338	20 The Board is not required to identify every drug to
339	339	21 identify every prescription drug that meets the criteria of
340	340	22 this subsection.
341	341	23 (b) The Board shall solicit public input on prescription
342	342	24 drugs thought to be creating affordability challenges that
343	343	25 meet the parameters of paragraphs (1) through (4) of
344	344	26 subsection (a). The Board shall determine whether to conduct a
345	345
346	346
347	347
348	348
349	349
350	350	HB4472 - 9 - LRB103 36317 CES 67585 b
351	351
352	352
353	353	HB4472- 10 -LRB103 36317 CES 67585 b HB4472 - 10 - LRB103 36317 CES 67585 b
354	354	HB4472 - 10 - LRB103 36317 CES 67585 b
355	355	1 full affordability review for the proposed prescription drugs
356	356	2 after compiling preliminary information about the cost of the
357	357	3 product, patient cost sharing for the product, health plan
358	358	4 spending on the product, stakeholder input, and other
359	359	5 information decided by the Board.
360	360	6 (c) If the Board conducts a review of the cost and
361	361	7 affordability of a prescription drug product, the review shall
362	362	8 determine whether use of the prescription drug product that is
363	363	9 fully consistent with the labeling approved by the United
364	364	10 States Food and Drug Administration or standard medical
365	365	11 practice has led or will lead to affordability challenges for
366	366	12 the State health care system or high out-of-pocket costs for
367	367	13 patients.
368	368	14 (d) The information to conduct an affordability review may
369	369	15 include, but is not limited to, any document and research
370	370	16 related to the manufacturer's selection of the introductory
371	371	17 price or price increase of the prescription drug product,
372	372	18 patient assistance program or programs specific to the
373	373	19 product, estimated or actual manufacturer product price
374	374	20 concessions in the market, net product cost to State payers,
375	375	21 and other information as determined by the Board.
376	376	22 (e) Failure of a manufacturer to provide the Board with
377	377	23 the information for an affordability review does not affect
378	378	24 the authority of the Board to conduct such a review.
379	379	25 (f) If the Board finds that the spending on a prescription
380	380	26 drug product reviewed under this Section has led or will lead
381	381
382	382
383	383
384	384
385	385
386	386	HB4472 - 10 - LRB103 36317 CES 67585 b
387	387
388	388
389	389	HB4472- 11 -LRB103 36317 CES 67585 b HB4472 - 11 - LRB103 36317 CES 67585 b
390	390	HB4472 - 11 - LRB103 36317 CES 67585 b
391	391	1 to an affordability challenge, the Board shall establish an
392	392	2 upper payment limit considering exceptional administrative
393	393	3 costs related to the distribution of the drug in the State.
394	394	4 (g) The upper payment limit applies to all purchases and
395	395	5 payor reimbursements of the prescription drug product intended
396	396	6 for use by individuals in the State, in person, by mail, or by
397	397	7 other means.
398	398	8 (h) Any information submitted to the Board in accordance
399	399	9 with this Section shall be subject to public inspection only
400	400	10 to the extent allowed under the Freedom of Information Act.
401	401	11 (i) This Section may not be construed to prevent a
402	402	12 manufacturer from marketing a prescription drug product
403	403	13 approved by the United States Food and Drug Administration
404	404	14 while the product is under review by the Board.
405	405	15 Section 30. Protections and other Board considerations.
406	406	16 (a) The Board shall examine how an upper payment limit
407	407	17 would affect 340B providers.
408	408	18 (b) In determining whether a drug creates an affordability
409	409	19 challenge or determining an upper payment limit amount, the
410	410	20 Board may not use cost-effectiveness analyses that include the
411	411	21 cost-per-quality adjusted life year or a similar measure to
412	412	22 identify subpopulations for which a treatment would be less
413	413	23 cost-effective due to severity of illness, age, or preexisting
414	414	24 disability. In addition, for any treatment that extends life,
415	415	25 if the Board uses cost-effectiveness results, the Board must
416	416
417	417
418	418
419	419
420	420
421	421	HB4472 - 11 - LRB103 36317 CES 67585 b
422	422
423	423
424	424	HB4472- 12 -LRB103 36317 CES 67585 b HB4472 - 12 - LRB103 36317 CES 67585 b
425	425	HB4472 - 12 - LRB103 36317 CES 67585 b
426	426	1 use results that weigh the value of all additional lifetime
427	427	2 gained equally for all patients no matter their severity of
428	428	3 illness, age, or preexisting disability.
429	429	4 (c) An upper payment limit is effective no sooner than 6
430	430	5 months after it has been announced.
431	431	6 (d) State-regulated health plans shall inform the Board of
432	432	7 how any upper payment limit-related cost savings are directed
433	433	8 to the benefit of enrollees, with a priority on enrollee cost
434	434	9 sharing.
435	435	10 (e) The upper payment limit shall not be inclusive of the
436	436	11 pharmacy dispensing fee or provider administration fee.
437	437	12 (f) State licensed independent pharmacies may not be
438	438	13 reimbursed less than the upper payment limit.
439	439	14 (g) The Board shall adopt the Medicare Maximum Fair Price
440	440	15 as defined in 42 U.S.C. 1320f(c)(3) for a prescription drug as
441	441	16 the upper payment limit for that prescription drug product
442	442	17 intended for use by individuals in this State, per subsection
443	443	18 (g) of Section 25.
444	444	19 Section 35. Remedies. The Attorney General shall have
445	445	20 authority to enforce this Act. The Attorney General may pursue
446	446	21 any available remedy under State law when enforcing this Act.
447	447	22 Section 40. Appeal of Board decisions.
448	448	23 (a) A person aggrieved by a decision of the Board may
449	449	24 request an appeal of the decision within 30 days after the
450	450
451	451
452	452
453	453
454	454
455	455	HB4472 - 12 - LRB103 36317 CES 67585 b
456	456
457	457
458	458	HB4472- 13 -LRB103 36317 CES 67585 b HB4472 - 13 - LRB103 36317 CES 67585 b
459	459	HB4472 - 13 - LRB103 36317 CES 67585 b
460	460	1 finding of the Board.
461	461	2 (b) The Board shall hear the appeal and make a final
462	462	3 decision within 60 days of the hearing.
463	463	4 (c) Any person aggrieved by a final decision of the Board
464	464	5 may petition for judicial review in accordance with the
465	465	6 provisions of the Administrative Review Law.
466	466	7 Section 45. Health Care Availability and Access Board
467	467	8 Fund. The Health Care Availability and Access Board Fund is
468	468	9 created as a special fund in the State treasury. The Board
469	469	10 shall be funded by an annual assessment on all manufacturers
470	470	11 whose products are sold in the State. All funds collected by
471	471	12 the Board from the assessments shall be deposited into the
472	472	13 Fund. The Fund shall be used only to provide funding for the
473	473	14 Board and for the purposes authorized under this Act,
474	474	15 including any costs expended by any State agency to implement
475	475	16 this Act. All interest earned on moneys in the Fund shall be
476	476	17 credited to the Fund. This Section may not be construed to
477	477	18 prohibit the Fund from receiving moneys from any other source
478	478	19 that does not create the appearance of a conflict of interest.
479	479	20 The Board shall be established using general funds, which
480	480	21 shall be repaid to the State with the assessments required
481	481	22 under this Section.
482	482	23 Section 50. Reports.
483	483	24 (a) On or before December 31 of each year, the Board shall
484	484
485	485
486	486
487	487
488	488
489	489	HB4472 - 13 - LRB103 36317 CES 67585 b
490	490
491	491
492	492	HB4472- 14 -LRB103 36317 CES 67585 b HB4472 - 14 - LRB103 36317 CES 67585 b
493	493	HB4472 - 14 - LRB103 36317 CES 67585 b
494	494	1 submit to the General Assembly a report that includes:
495	495	2 (1) price trends for prescription drug products;
496	496	3 (2) the number of prescription drug products that were
497	497	4 subject to Board review, including the results of the
498	498	5 review and the number and disposition of appeals and
499	499	6 judicial reviews of Board decisions; and
500	500	7 (3) any recommendations the Board may have on further
501	501	8 legislation needed to make prescription drug products more
502	502	9 affordable in this State.
503	503	10 (b) On or before June 1, 2025, the Health Care
504	504	11 Availability and Access Board shall submit a report to the
505	505	12 General Assembly about the operation of the generic drug
506	506	13 market in the United States that includes a review of
507	507	14 physician-administered drugs and considers:
508	508	15 (1) the prices of generic drugs on a year-over-year
509	509	16 basis;
510	510	17 (2) the degree to which generic drug prices affect
511	511	18 insurance premiums as reported by health insurers in this
512	512	19 State or other states that collect this information;
513	513	20 (3) recent and current trends in patient cost sharing
514	514	21 for generic drugs;
515	515	22 (4) the causes and prevalence of generic drug
516	516	23 shortages; and
517	517	24 (5) any other relevant study questions.
518	518	25 Section 55. Term expiration.
519	519
520	520
521	521
522	522
523	523
524	524	HB4472 - 14 - LRB103 36317 CES 67585 b
525	525
526	526
527	527	HB4472- 15 -LRB103 36317 CES 67585 b HB4472 - 15 - LRB103 36317 CES 67585 b
528	528	HB4472 - 15 - LRB103 36317 CES 67585 b
529	529	1 (a) The terms of the initial members and alternate members
530	530	2 of the Health Care Availability and Access Board shall expire
531	531	3 as follows:
532	532	4 (1) one member and one alternate member in 2028;
533	533	5 (2) 2 members and one alternate member in 2029; and
534	534	6 (3) 2 members, including the Chair of the Board, and
535	535	7 one alternate member in 2030.
536	536	8 (b) The terms of the initial members of the Health Care
537	537	9 Availability and Access Stakeholder Council shall expire as
538	538	10 follows:
539	539	11 (1) 5 members in 2028;
540	540	12 (2) 5 members in 2029; and
541	541	13 (3) 5 members in 2030.
542	542	14 Section 97. Severability. If any provision of this Act or
543	543	15 the application thereof to any person or circumstance is held
544	544	16 invalid for any reason in a court of competent jurisdiction,
545	545	17 the invalidity does not affect other provisions or any other
546	546	18 application of this Act that can be given effect without the
547	547	19 invalid provision or application, and for this purpose the
548	548	20 provisions of this Act are declared severable.
549	549	21 Section 900. The State Finance Act is amended by adding
550	550	22 Section 5.1015 as follows:
551	551	23 (30 ILCS 105/5.1015 new)
552	552
553	553
554	554
555	555
556	556
557	557	HB4472 - 15 - LRB103 36317 CES 67585 b
558	558
559	559
560	560	HB4472- 16 -LRB103 36317 CES 67585 b HB4472 - 16 - LRB103 36317 CES 67585 b
561	561	HB4472 - 16 - LRB103 36317 CES 67585 b
562	562	1 Sec. 5.1015. The Health Care Availability and Access Board
563	563	2 Fund.
564	564
565	565
566	566
567	567
568	568
569	569	HB4472 - 16 - LRB103 36317 CES 67585 b